Kezar Life Sciences Inc. (KZR)
4.16
0.10 (2.46%)
At close: Apr 17, 2025, 3:58 PM
4.16
0.00%
After-hours: Apr 17, 2025, 04:05 PM EDT
2.46% (1D)
| Bid | 3.88 |
| Market Cap | 30.39M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -83.74M |
| EPS (ttm) | -11.49 |
| PE Ratio (ttm) | -0.36 |
| Forward PE | -0.55 |
| Analyst | Hold |
| Ask | 5.25 |
| Volume | 6,089 |
| Avg. Volume (20D) | 32,762.3 |
| Open | 4.14 |
| Previous Close | 4.06 |
| Day's Range | 4.11 - 4.32 |
| 52-Week Range | 3.62 - 9.20 |
| Beta | 0.61 |
About KZR
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b ...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 21, 2018
Employees 55
Stock Exchange NASDAQ
Ticker Symbol KZR
Analyst Forecast
According to 2 analyst ratings, the average rating for KZR stock is "Hold." The 12-month stock price forecast is $9, which is an increase of 116.35% from the latest price.
Stock Forecasts6 months ago
+42.1%
Kezar Life Sciences shares are trading higher afte...
Unlock content with
Pro Subscription
